Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

EVOLUTION IN FRAGILITY IN PEOPLE ON THE WAITING LIST FOR A KIDNEY TRANSPLANT

19 maggio 2026 aggiornato da: Anna Bach Pascual, Hospital del Mar

This study looks at how the physical and emotional health of people changes while they wait for a kidney transplant. Waiting for an organ can take a long time. During this period, some patients become "frail." This means they lose strength and are at a higher risk for health problems.

The main goal is to follow these patients over time to better understand their needs. Researchers will use a mobile app to collect information directly from patients about how they feel and their quality of life. The study will also include personal interviews to learn about the patients' experiences and any difficulties they face when using technology.

The results of this study will help to:

  • Identify early which patients are losing strength or health.
  • Improve the support that nurses provide during the transplant waiting period.
  • Make sure that digital health tools are easy for everyone to use. In short, this work aims to help patients reach the day of their surgery in the best possible condition.

Panoramica dello studio

Descrizione dettagliata

Study Design and Framework This research employs a convergent-parallel mixed-methods design to evaluate frailty dynamics and patient-reported outcomes in kidney transplant (KT) candidates. The quantitative component is a longitudinal observational study, while the qualitative component is grounded in Heideggerian hermeneutic phenomenology to explore the lived experience of patients during the waiting list period.

Quantitative Procedures and Data Collection Participants will be recruited during their initial KT evaluation at Hospital del Mar (Barcelona). Frailty will be assessed using the Fried Phenotype (assessing weight loss, exhaustion, physical activity, walk time, and grip strength) at baseline and subsequently every six months while the patient remains on the waiting list.

To monitor Patient-Reported Outcome Measures (PROMs), the study utilizes the PROMIS-29 v2.0 questionnaire. This instrument covers seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles/activities, and pain interference. Data collection will be performed via a digital platform (ePROMs), allowing for real-time monitoring. For patients facing technological or language barriers, an Advanced Practice Nurse (APN) will provide support to ensure data completeness and minimize selection bias.

Qualitative Exploration A purposive sample of participants will undergo in-depth semi-structured interviews. These sessions will focus on the subjective meaning of frailty, the impact of the waiting period on daily life, and the experience of using digital health tools. Interviews will be audio-recorded, transcribed verbatim, and analyzed using thematic analysis to identify core existential themes.

Quality Assurance and Data Management

  • Data Validation: A data dictionary has been developed, defining each variable, its source, and acceptable ranges to ensure consistency.
  • Source Data Verification: Data entered into the electronic Case Report Form (eCRF) will be cross-referenced with electronic medical records to ensure accuracy.
  • Standard Operating Procedures (SOPs): Specific SOPs are in place for patient recruitment, the standardized administration of physical performance tests (e.g., handgrip strength using a dynamometer), and the management of technical issues with the ePROM platform.

Statistical Analysis Plan (SAP) Quantitative data will be analyzed using SPSS v.25. Descriptive statistics will summarize baseline characteristics. Longitudinal changes in frailty scores and PROMs will be analyzed using linear mixed models or generalized estimating equations (GEE) to account for repeated measures. The relationship between frailty status and health-related quality of life (HRQoL) will be assessed using correlation coefficients and multivariate regression models adjusted for age, comorbidity, and time on dialysis.

Missing Data Plan The study aims to minimize missing data through APN-led follow-up. If data are missing at random, multiple imputation techniques will be considered. For patients unable to use digital tools, paper-based alternatives or assisted entry will be provided to reduce non-response bias.

Sample Size Assessment The sample size is based on the prevailing activity of the kidney transplant unit, aiming to include all eligible candidates over the recruitment period (estimated N ≈ 150-200) to ensure sufficient power for detecting longitudinal changes in frailty prevalence and its association with PROMs.

Tipo di studio

Osservativo

Iscrizione (Stimato)

150

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Anna Bach Pascual, RN, MSN i PhDc
  • Numero di telefono: +34 648653656
  • Email: abach@hmar.cat

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study population consists of adult patients with end-stage renal disease (ESRD) managed at the Nephrology Department of Hospital del Mar (Barcelona). This includes patients receiving renal replacement therapy (hemodialysis or peritoneal dialysis) or those in the pre-dialysis stage who have been referred for kidney transplant evaluation. The population is characterized by a high burden of comorbidity and varying degrees of physical frailty associated with chronic uremia and long-term dialysis treatment.

Descrizione

Inclusion Criteria:

  • Patients aged 18 years or older.
  • Diagnosed with Chronic Kidney Disease (CKD) Stage 5.
  • Currently undergoing clinical evaluation for kidney transplantation on the deceased-donor kidney transplant waiting list at Hospital del Mar.
  • Ability to understand and provide written informed consent.
  • Ability to use or have access to a digital device (smartphone/tablet) for ePROM completion.

Exclusion Criteria:

  • Severe cognitive impairment or psychiatric disorders that prevent the reliable completion of questionnaires or physical tests.
  • Major physical disability that precludes the assessment of gait speed or handgrip strength (e.g., bilateral leg amputation or severe hand deformity).
  • Acute medical condition requiring hospitalization at the time of enrollment (assessment can be deferred).
  • Language barrier that prevents understanding the study or the qualitative interview.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Kidney Transplant Candidates

This is a single-group observational cohort of adult patients with Stage 5 Chronic Kidney Disease (CKD) who are undergoing evaluation for or are already active on the deceased-donor kidney transplant waiting list.

The nature of this group is characterized by the transition from advanced chronic illness to potential transplantation. All participants will undergo a longitudinal follow-up (every 6 months) to monitor frailty status and health-related quality of life. The study focuses on the "frailty dynamics" during the waiting period.

Data collection includes:

Physical assessments (Fried Phenotype: handgrip strength, gait speed).

Patient-Reported Outcome Measures (PROMs) via the PROMIS-29 digital platform (ePROMs).

Qualitative hermeneutic interviews for a selected subset to explore the lived experience of frailty.

No clinical intervention or medication will be administered as part of this study protocol.

Intervention Description (Intervention 1: Frailty Assessment) Systematic multidimensional assessment of frailty conducted by an Advanced Practice Nurse (APN) specialized in nephrology.

Components of assessment:

  1. Fried Phenotype: Objective measurement of 5 criteria: unintended weight loss, self-reported exhaustion, level of physical activity, gait speed (measured over 4 meters), and handgrip strength (measured using a calibrated hydraulic dynamometer).
  2. Clinical Frailty Scale (CFS): Global clinical judgment based on fitness and functional independence.
  3. SPPB (Short Physical Performance Battery): To assess balance, gait, and lower limb strength (chair stands).

Frequency: Assessments will be performed at baseline (enrollment) and every 6 months (+/- 1 month) throughout the duration of the patient's presence on the kidney transplant waiting list.

All measurements follow standardized protocols to minimize inter-observer variability and ensure data reproducibility.

Altri nomi:
  • Fried Frailty Phenotype Assessment
  • Physical Performance Monitoring
  • Comprehensive Frailty Evaluation
  • Clinical Frailty Scale (CFS)

Implementation of a digital health strategy to monitor patient-reported outcomes throughout the kidney transplant waiting list period.

Core Instrument: Participants will complete the PROMIS-29 v2.0 (Patient-Reported Outcomes Measurement Information System) questionnaire. This validated tool assesses 7 key health domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Roles/Activities, and Pain Interference, plus a single-item pain intensity scale.

Procedure:

  1. Data Collection: Administered via a secure digital platform (ePROMs) accessible via smartphone, tablet, or computer.
  2. Frequency: Data will be collected at baseline and subsequently every 6 months, coinciding with clinical frailty assessments.
  3. Support: An Advanced Practice Nurse (APN) provides technical onboarding and follows up on non-compliance to ensure data completeness and address the digital divide.

This intervention is purely observational and aimed at capturing the patient's subjectiv

Altri nomi:
  • PROMIS-29 v2.0 Questionnaire
  • Digital Health Monitoring
  • Patient-Reported Quality of Life Assessment

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Frailty Status (Fried Phenotype)
Lasso di tempo: Baseline, 6 months, 12 months

Frailty is assessed using the Fried Phenotype, which includes five criteria: unintended weight loss, self-reported exhaustion, low physical activity, slow gait speed (4-meter walk test), and weak grip strength (measured by a hydraulic dynamometer).Scoring: Each criterion is scored 0 (absent) or 1 (present).

Non-frail: 0 points Pre-frail: 1-2 points Frail: 3-5 points

The primary outcome is the longitudinal change or transition between these categories during the waiting list period.

Baseline, 6 months, 12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Health-Related Quality of Life (HRQoL)
Lasso di tempo: Baseline, 6 months, 12 months

Assessed using the PROMIS-29 v2.0 questionnaire. This tool measures 7 domains: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference.

Scoring: Each domain is scored on a T-score metric, where 50 is the mean of the relevant reference population (SD = 10). Higher scores represent more of the concept being measured (e.g., higher anxiety, better physical function).

Baseline, 6 months, 12 months
Clinical Transitions on the Waiting List
Lasso di tempo: 12 Months

Incidence of major clinical events that alter the patient's status.

Events monitored: Successful kidney transplantation, removal from the waiting list due to clinical worsening, or death while on the list.

12 Months
Digital Tool Usability and Barriers
Lasso di tempo: 12 months
Evaluation of the feasibility and barriers to using the ePROM platform. Assessment: Measured through the completion rate of the digital questionnaires and the qualitative feedback regarding technological challenges or the "digital divide" as identified during APN follow-up.
12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 aprile 2026

Completamento primario (Stimato)

1 aprile 2028

Completamento dello studio (Stimato)

1 aprile 2028

Date di iscrizione allo studio

Primo inviato

19 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

19 maggio 2026

Primo Inserito (Effettivo)

26 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

26 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data (IPD) will not be shared at this time to protect the confidentiality of the participants and the integrity of the ongoing doctoral thesis. The data collected involves sensitive clinical information and qualitative interviews within a specific, small-scale clinical setting (kidney transplant waiting list).

However, the study results will be disseminated through peer-reviewed publications and conference presentations. Requests for access to aggregate data or specific methodological details can be directed to the Principal Investigator and will be considered on a case-by-case basis, subject to approval by the Institutional Review Board (CEIm) and in compliance with the General Data Protection Regulation (GDPR)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Qualità della vita

Prove cliniche su Longitudinal Frailty Assessment

Sottoscrivi